Neurological complications during treatment of middle east respiratory syndrome

Journal of Clinical Neurology (Korea)

Volumn 13, Issue 3, 2017, Pages 227-233

  Kim, Jee Eun ^a   Heo, Jae Hyeok ^a   Kim, Hye Ok ^a   Song, Sook Hee ^a   Park, Sang Soon ^a   Park, Tai Hwan ^a   Ahn, Jin Young ^a   Kim, Min Ky ^a   Choi, Jae Phil ^a  

^a Seoul Medical Center   (South Korea)

Author keywords

Guillain Barr syndrome; Middle East respiratory syndrome; Neurological complications; Peripheral neuropathy

Indexed keywords

EID: 85026464953     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2017.13.3.227     Document Type: Article

References (30)

1. who.int [internet]. Middle East Respiratory Syndrome Coronavirus Infections-Disease Outbreak News. [cited 2016 Nov 22]. Available from: http://www.who.int/emergencies/mers-cov/en.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-1820.
3. mers.go.kr [internet]. Summary of MERS Statistics in the Republic of Korea. [cited 2016 Nov 22]. Available from: https://www.mers.go.kr/mers/html/jsp/main.jsp.
4. WHO Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5:ecurrents.outbreaks.0bf719e352e7478f8ad85f a30127ddb8.
5. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuro-invasiveness and neuropathogenesis. Virus Res 2014;194:145-158.
6. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301-306.
7. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 2015;43:495-501.
8. Algahtani H, Subahi A, Shirah B. Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Rep Neurol Med 2016;2016:3502683.
9. who.int [internet]. Technical Guidance on Laboratory: Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2016 Nov 22]. Available from: http://www.who.int/csr/disease/coronavirus_infec-tions/technical-guidance-laboratory/en.
10. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-810.
11. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
12. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.
13. Chong YP, Song JY, Seo YB, Choi JP, Shin HS; Rapid Response Team. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother 2015;47:212-222.
14. Wakerley BR, Uncini A, Yuki N; GBS Classification Group; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol 2014;10:537-544.
15. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-1106.
16. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychi- atry 2013;84:576-583.
17. Galvin R, Bråthen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA; EFNS. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 2010;17:1408-1418.
18. Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Pract Neurol 2015;15:90-99.
19. Dhand UK. Clinical approach to the weak patient in the intensive care unit. Respir Care 2006;51:1024-1040; discussion 1040-1041.
20. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2011;10:931-941.
21. van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Para-paretic Guillain-Barré syndrome. Neurology 2014;82:1984-1989.
22. Briani C, Chemello L, Zara G, Ermani M, Bernardinello E, Ruggero S, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 2006;67:781-785.
23. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000; 23:433-435.
24. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008;14:318-321.
25. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McAr-thur JC, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008;64:566-572.
26. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386:995-1007.
27. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000;74:8913-8921.
28. Chan JF, Chan KH, Choi GK, To KK, Tse H, Cai JP, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013;207:1743-1752.
29. Tsai LK, Hsieh ST, Chao CC, Chen YC, Lin YH, Chang SC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004;61:1669-1673.
30. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol 2004;251:1227-1231.